Cargando…

Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse

PURPOSE: To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone‐iodine (PVP‐I) against SARS‐CoV‐2 (‘corona virus’) to mitigate the risk and transmission of the virus in the dental practice. MATERIALS AND METHODS: The severe acute respiratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidra, Avinash S., Pelletier, Jesse S, Westover, Jonna B, Frank, Samantha, Brown, Seth M, Tessema, Belachew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300649/
https://www.ncbi.nlm.nih.gov/pubmed/32511851
http://dx.doi.org/10.1111/jopr.13209
_version_ 1783547594230726656
author Bidra, Avinash S.
Pelletier, Jesse S
Westover, Jonna B
Frank, Samantha
Brown, Seth M
Tessema, Belachew
author_facet Bidra, Avinash S.
Pelletier, Jesse S
Westover, Jonna B
Frank, Samantha
Brown, Seth M
Tessema, Belachew
author_sort Bidra, Avinash S.
collection PubMed
description PURPOSE: To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone‐iodine (PVP‐I) against SARS‐CoV‐2 (‘corona virus’) to mitigate the risk and transmission of the virus in the dental practice. MATERIALS AND METHODS: The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) USA‐WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone‐iodine (PVP‐I) as the sole active ingredient. The PVP‐I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end‐point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated. RESULTS: PVP‐I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS‐CoV‐2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS‐CoV‐2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact. CONCLUSIONS: PVP‐I oral antiseptic preparations rapidly inactivated SARS‐CoV‐2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP‐I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP‐I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID‐19 pandemic.
format Online
Article
Text
id pubmed-7300649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73006492020-06-18 Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse Bidra, Avinash S. Pelletier, Jesse S Westover, Jonna B Frank, Samantha Brown, Seth M Tessema, Belachew J Prosthodont Original Manuscripts PURPOSE: To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone‐iodine (PVP‐I) against SARS‐CoV‐2 (‘corona virus’) to mitigate the risk and transmission of the virus in the dental practice. MATERIALS AND METHODS: The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) USA‐WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone‐iodine (PVP‐I) as the sole active ingredient. The PVP‐I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end‐point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated. RESULTS: PVP‐I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS‐CoV‐2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS‐CoV‐2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact. CONCLUSIONS: PVP‐I oral antiseptic preparations rapidly inactivated SARS‐CoV‐2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP‐I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP‐I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID‐19 pandemic. John Wiley and Sons Inc. 2020-06-16 2020-07 /pmc/articles/PMC7300649/ /pubmed/32511851 http://dx.doi.org/10.1111/jopr.13209 Text en © 2020 The Authors. Journal of Prosthodontics published by Wiley Periodicals LLC on behalf of American College of Prosthodontists https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Manuscripts
Bidra, Avinash S.
Pelletier, Jesse S
Westover, Jonna B
Frank, Samantha
Brown, Seth M
Tessema, Belachew
Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title_full Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title_fullStr Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title_full_unstemmed Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title_short Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse
title_sort rapid in‐vitro inactivation of severe acute respiratory syndrome coronavirus 2 (sars‐cov‐2) using povidone‐iodine oral antiseptic rinse
topic Original Manuscripts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300649/
https://www.ncbi.nlm.nih.gov/pubmed/32511851
http://dx.doi.org/10.1111/jopr.13209
work_keys_str_mv AT bidraavinashs rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse
AT pelletierjesses rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse
AT westoverjonnab rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse
AT franksamantha rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse
AT brownsethm rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse
AT tessemabelachew rapidinvitroinactivationofsevereacuterespiratorysyndromecoronavirus2sarscov2usingpovidoneiodineoralantisepticrinse